MCL Archives - Insights

Seasonal Viruses: What To Expect and What’s Next in Diagnostics

Mayo Clinic Laboratories — Thu, 08 Oct 2026 13:00:00 +0000

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss Mayo Clinic’s new collaboration with Thermo Fisher and the latest on the Protecting Access to Medicare Act (PAMA). Later, Dr. Pritt welcomes Matt Binnicker, Ph.D., Mayo Clinic Laboratories’ chief scientific officer and a leader in novel diagnostics for viral infections, to explore seasonal virus activity.

The post Seasonal Viruses: What To Expect and What’s Next in Diagnostics appeared first on Insights.

A problem-solving toolbox: DMAIC, A3, and PDSA

MCL Education — Mon, 05 Oct 2026 10:00:00 +0000

Review how problem-solving methods can work together to define and measure a problem, identify root causes, test potential solutions, and sustain successful improvements.

The post A problem-solving toolbox: DMAIC, A3, and PDSA appeared first on Insights.

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Diagnostic criteria

MCL Education — Mon, 28 Sep 2026 10:00:00 +0000

This microlearning reviews myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), with a focus on the 2023 International MOGAD Panel diagnostic criteria.

The post Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Diagnostic criteria appeared first on Insights.

Mayo Clinic Laboratories invests in Pathology Asia Holdings and LifeStrands Genomics to advance diagnostics and precision medicine

jgilligan1 — Wed, 23 Sep 2026 14:00:00 +0000

Mayo Clinic Laboratories and Pathology Asia Holdings (PAH) have announced a strategic investment and collaboration aimed at expanding access to advanced diagnostics and precision medicine across Southeast Asia, Australia and New Zealand.

The post Mayo Clinic Laboratories invests in Pathology Asia Holdings and LifeStrands Genomics to advance diagnostics and precision medicine appeared first on Insights.

Insulin analogs testing

Robin Huiras-Carlson — Tue, 22 Sep 2026 13:15:00 +0000

Learn more about how Mayo Clinic Laboratories first-in-class insulin analogs assay uses liquid chromatography-high resolution mass spectrometry to provide clinicians with a highly specific way to identify and differentiate human insulin from multiple synthetic insulin analogs from a single blood sample. By overcoming the limitations of traditional immunoassays, the test delivers greater diagnostic clarity in complex hypoglycemia cases, helping clinicians reach accurate diagnoses faster and guide more effective patient care.

The post Insulin analogs testing appeared first on Insights.

Closing a Diagnostic Gap for Chronic Diarrhea

Mayo Clinic Laboratories — Thu, 17 Sep 2026 13:00:00 +0000

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss seasonal vaccination planning and survey findings on laboratory industry growth. Later, Leslie Donato, Ph.D., a clinical chemist at Mayo Clinic, shares how an innovative testing panel is improving the diagnosis of bile acid malabsorption.

The post Closing a Diagnostic Gap for Chronic Diarrhea appeared first on Insights.

Going beyond standard testing to diagnose rare autoimmune skin diseases

Chris Bahnsen — Wed, 16 Sep 2026 13:45:00 +0000

Specialized immunofluorescence testing helps uncover rare autoimmune blistering diseases, identify underlying cancers, and guide precise treatment, improving diagnostic accuracy and outcomes for patients with challenging skin disorders.

The post Going beyond standard testing to diagnose rare autoimmune skin diseases appeared first on Insights.

Improve Alzheimer’s disease detection with innovative, FDA-cleared PrecivityAD2 blood biomarker testing

Robin Huiras-Carlson — Tue, 15 Sep 2026 13:00:00 +0000

Join Mayo Clinic Laboratories and C2N Diagnostics for our webinar exploring how the evolution of blood biomarker testing for Alzheimer's disease has expanded access to earlier, less-invasive diagnosis. Focusing on the newly FDA-cleared PrecivityAD2 blood test, which is offered by Mayo Clinic Laboratories in collaboration with C2N Diagnostics, the discussion will highlight how results from blood biomarker testing can support timely diagnosis, informed clinical decision-making, and improved patient care.

The post Improve Alzheimer’s disease detection with innovative, FDA-cleared PrecivityAD2 blood biomarker testing appeared first on Insights.

UNC Health: Reducing redundant testing and achieving improved answers

Robin Huiras-Carlson — Tue, 08 Sep 2026 13:00:00 +0000

Collaborating with Mayo Clinic Laboratories, UNC Health streamlined neuroimmunology test ordering — eliminating outmoded testing and elevating diagnostic accuracy.

The post UNC Health: Reducing redundant testing and achieving improved answers appeared first on Insights.

Metagenomic sequencing: A revolutionary approach to aid in the diagnosis of serious and complex infections

Robin Huiras-Carlson — Fri, 28 Aug 2026 15:00:00 +0000

Join Mayo Clinic Laboratories for our webinar exploring the expanding role of precision diagnostics in the evaluation of serious and potentially life-threatening infections. Focusing on metagenomic sequencing available from Mayo Clinic Laboratories, including the Karius Spectrum plasma test, which is offered by Mayo Clinic Laboratories in collaboration with Karius, participants will gain an overview of microbial cell-free DNA (mcfDNA) metagenomic sequencing, including clinical decision-making around test ordering, appropriate clinical indications, and how to interpret and apply results to support timely diagnosis and patient management.

The post Metagenomic sequencing: A revolutionary approach to aid in the diagnosis of serious and complex infections appeared first on Insights.